StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Actinium Pharmaceuticals's total assets was $40.16M at Jun 30, 2026. For fiscal 2025 it was $51.78M, down 32.7% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $114.19M in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$51.78M-32.7%
FY2024Dec 31, 2024$76.90M-5.6%
FY2023Dec 31, 2023$81.45M-28.7%
FY2022Dec 31, 2022$114.19M+42.1%
FY2021Dec 31, 2021$80.39M+21.1%
FY2020Dec 31, 2020$66.40M+469.0%
FY2019Dec 31, 2019$11.67M-21.6%
FY2018Dec 31, 2018$14.89M-18.8%
FY2017Dec 31, 2017$18.34M-18.6%
FY2016Dec 31, 2016$22.53M-15.3%
FY2015Dec 31, 2015$26.59M+251.3%
FY2014Dec 31, 2014$7.57M+31.3%
FY2013Dec 31, 2013$5.77M-0.4%
FY2012Dec 31, 2012$5.79M-6.6%
FY2011Dec 31, 2011$6.20M+4133564.7%
FY2010Dec 31, 2010$150–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$40.16M-36.3%
Q1 FY2026Mar 31, 2026$45.44M-33.8%
Q4 FY2025Dec 31, 2025$51.78M-32.7%
Q3 FY2025Sep 30, 2025$56.15M-31.6%
Q2 FY2025Jun 30, 2025$63.02M-29.9%
Q1 FY2025Mar 31, 2025$68.65M-22.3%
Q4 FY2024Dec 31, 2024$76.90M-5.6%
Q3 FY2024Sep 30, 2024$82.11M-7.7%
Q2 FY2024Jun 30, 2024$89.86M-9.3%
Q1 FY2024Mar 31, 2024$88.35M-13.4%
Q4 FY2023Dec 31, 2023$81.45M-28.7%
Q3 FY2023Sep 30, 2023$88.94M-23.9%
Q2 FY2023Jun 30, 2023$99.05M-18.7%
Q1 FY2023Mar 31, 2023$102.03M+36.8%
Q4 FY2022Dec 31, 2022$114.19M+42.1%
Q3 FY2022Sep 30, 2022$116.82M+38.3%
Q2 FY2022Jun 30, 2022$121.80M+44.2%
Q1 FY2022Mar 31, 2022$74.56M-0.7%
Q4 FY2021Dec 31, 2021$80.39M+21.1%
Q3 FY2021Sep 30, 2021$84.48M+67.2%
Q2 FY2021Jun 30, 2021$84.45M+50.9%
Q1 FY2021Mar 31, 2021$75.10M+797.9%
Q4 FY2020Dec 31, 2020$66.40M+469.0%
Q3 FY2020Sep 30, 2020$50.53M+209.6%
Q2 FY2020Jun 30, 2020$55.96M+156.5%
Q1 FY2020Mar 31, 2020$8.36M-31.6%
Q4 FY2019Dec 31, 2019$11.67M-21.6%
Q3 FY2019Sep 30, 2019$16.32M+3.9%
Q2 FY2019Jun 30, 2019$21.82M-3.4%
Q1 FY2019Mar 31, 2019$12.24M-56.5%
Q4 FY2018Dec 31, 2018$14.89M-18.8%
Q3 FY2018Sep 30, 2018$15.70M-27.7%
Q2 FY2018Jun 30, 2018$22.58M+74.0%
Q1 FY2018Mar 31, 2018$28.14M+54.2%
Q4 FY2017Dec 31, 2017$18.34M-18.6%
Q3 FY2017Sep 30, 2017$21.72M+25.8%
Q2 FY2017Jun 30, 2017$12.98M–
Q1 FY2017Mar 31, 2017$18.24M–
Q4 FY2016Dec 31, 2016$22.53M–
Q3 FY2016Sep 30, 2016$17.26M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?